2913161-19-8

ACBI2 (80?mg/kg, p.o., once daily) significantly inhibits tumor growth in an A549 xenograft mice model^[1].
ACBI2 (5-100 mg/kg, p.o., tumors collected 24 or 48?h after treatment) dose-dependently degrades tumor SMARCA2 in A549 engrafted tumor bearing mice (IHC staining)^[1].
ACBI2 (30 mg/kg, p.o., mice) shows oral bioavailability of 22%^[1].